We are on a path of expansion which is reflected through our acquisition of a manufacturing facility in Gujarat and completion of our biosimilar facility in Chennai. Commercialization of the biosimilar range is expected in Q3 2022. Additionally, we have now opened three new offices in Spain, UAE, and Costa Rica in order to expand our reach and range in the regions.
Prime Group starts as an API company in Kolkata.
Forays into the FDF export business and plans to expand internationally.
Enters the African Markets.
Enters the South East Asian Markets.
Enters the Latin & Central American Markets.
Officially starts its first global office in Vietnam and sets up the R&D Service vertical.
Invests into Regenix Group to set up a greenfield EU Compliant biosimilars facility and expands it's footprint into 50+ countries globally
Acquires a pharma company with an FDF plant in India and opens global offices in UAE, Spain, and Costa Rica.